Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

WycklyTrader Oct. 24 at 7:53 PM

$QNCX CGEM potential base breakout with upcoming FDA catalysts. 52wk high swingS: $NUVB $RLAY $TOI $FDMT ...

0 · Reply

ADSlay Oct. 24 at 4:26 PM

$QNCX there are big 'reputation' costs associated for public companies to be partnering with others. They don't just randomly partner with small companies unless there is moat, especially not with someone like $QNCX who is a turnaround story, pre-revenue, and no proven product. I am sure $OPCH must've agreed to partner only after performing their thorough due-diligence. yes, no one refuses extra revenue coming in, but when you're a responsible $5 billion publicly traded company, you don't just randomly partner with anyone. there is a 'brand' image they've to protect.

0 · Reply

kb60521 Oct. 24 at 3:22 PM

$QNCX No nothing. but again no one is selling also. Interesting. Want to see where this will take us......

0 · Reply

ADSlay Oct. 23 at 5:03 PM

$QNCX Anything can happen in biotech world, but why would a $5 billion company like $OPCH agree to a strategic partnership with a $100 million company like $QNCX? That alone makes $QNCX a great risk:reward opportunity besides being a Ph3 asset that has full Regulatory support from FDA.

2 · Reply

ADSlay Oct. 23 at 1:12 PM

Thanks for sharing. Yes, $QNCX Management regularly updates their presentation and is a great resource for research. Why would a $5 billion company associate with a $100 million company? Think why $OPCH would partner with $QNCX ? When one is such a big company, one doesn't associate with random biotech microcaps with unproven product. Think about it.

1 · Reply

ADSlay Oct. 20 at 4:57 PM

$QNCX CEO &CMO in Panel discussion folks🚀🚀🚀 From X today: $QNCX Investors: Looking forward to attending the 2025 Maxim Growth Summit this week where our CEO & CMO Dirk Thye, M.D., will participate in the Unlocking Value in Late-Stage/Commercial Rare Disease panel discussion.

2 · Reply

wolfhead Oct. 18 at 12:46 AM

$QNCX What the hell with the Huge AH drop? Phase 2 setback news?

1 · Reply

dv1809 Oct. 17 at 10:33 PM

$QNCX

0 · Reply

QNCXtothemoon Oct. 17 at 10:01 PM

$QNCX https://ir.quincetx.com/node/9586/html

0 · Reply

kb60521 Oct. 17 at 4:27 PM

$QNCX People are just scraping and making money with the cents. One day there won't be any shares to buy and it will be too late......

0 · Reply

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 5:12 PM EDT - 23 days ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Sep 25, 2025, 4:05 PM EDT - 4 weeks ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 24, 2025, 1:13 AM EDT - 4 weeks ago

Quince Therapeutics, Inc. - Special Call

Sep 11, 2025, 4:05 PM EDT - 6 weeks ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 7 weeks ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 4 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 15, 2025, 9:50 AM EDT - 5 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 13, 2025, 8:00 AM EDT - 5 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 9 months ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 9 months ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 9 months ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 9 months ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 9 months ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 9 months ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Participate at Investor Events in January 2024

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

WycklyTrader Oct. 24 at 7:53 PM

$QNCX CGEM potential base breakout with upcoming FDA catalysts. 52wk high swingS: $NUVB $RLAY $TOI $FDMT ...

0 · Reply

ADSlay Oct. 24 at 4:26 PM

0 · Reply

kb60521 Oct. 24 at 3:22 PM

$QNCX No nothing. but again no one is selling also. Interesting. Want to see where this will take us......

0 · Reply

ADSlay Oct. 23 at 5:03 PM

2 · Reply

ADSlay Oct. 23 at 1:12 PM

1 · Reply

ADSlay Oct. 20 at 4:57 PM

2 · Reply

wolfhead Oct. 18 at 12:46 AM

$QNCX What the hell with the Huge AH drop? Phase 2 setback news?

1 · Reply

dv1809 Oct. 17 at 10:33 PM

$QNCX

0 · Reply

QNCXtothemoon Oct. 17 at 10:01 PM

$QNCX https://ir.quincetx.com/node/9586/html

0 · Reply

kb60521 Oct. 17 at 4:27 PM

$QNCX People are just scraping and making money with the cents. One day there won't be any shares to buy and it will be too late......

0 · Reply

ActaVerba Oct. 17 at 1:05 PM

#QNCX Positive data from Attest study in 6-9 year old population. Neat is repeated in this population, using their higher dose of eDSP with efficacy focus on 6-9 population, although a few older have been recruited, this will not affect final efficacy. Using RmICARS - this should capture results better and prevent dilution. STRONG safety profile. Enhanced site training worldwide. FDA fast track and orphan drug status. Excellent management with proven track record. Funding to see them through TopLine. Results Q1 2026. My personal guess would be February for readout. Please note this is not financial advice and only my notes, do your own research. #Bullish #QNCX #Q12026

0 · Reply

WycklyTrader Oct. 16 at 1:55 AM

$INO & $QNCX potential base breakouts with upcoming FDA catalysts. $NIO $GME $PLUG : CGEM , AIRS insider buys + high short interest.

1 · Reply

ActaVerba Oct. 14 at 2:17 PM

$QNCX Hugely exciting pipeline that this technology can be used for! How many diseases out there rely on steroids but are hampered by toxicity. Nearly everyone will know someone who has been badly bloated with various unwanted side effects from steroids during treatment. This could be massive. This is not going to stay at these prices for long. It’s P3 for AT but safety from thousands of infusions is solid. Not financial advice… But BULLISH 🚀🚀

0 · Reply

ActaVerba Oct. 14 at 1:16 PM

$QNCX

0 · Reply

Alcryptino Oct. 14 at 2:24 AM

$QNCX just 5x already, we all know you want to!

0 · Reply

McGinvests Oct. 10 at 3:36 PM

$CRDF just getting pounded today 😫 $QNCX $NKTX

2 · Reply

kb60521 Oct. 10 at 2:55 PM

$QNCX wow, such a good news and such a pathetic response by market. I don't remember the numbers now, but sometime back I was doing calculations and thought the existing obligations are already making the company bit costly or something, like I was looking at 500 million or so. Do any of you think so or found the same? please share.... despite all that the company should value more than even that 500 million, I think we can give weightage to the pipeline, but more weightage to the mechanism itself. I strongly believe the mechanism is worth a lot, and many things can be achieved using the same. Please do share your thoughts......

0 · Reply

ADSlay Oct. 10 at 2:47 PM

$BTC $CDTX $QNCX $TE $VIR It is interesting to see both QNCX and VIR on the same list. Did you know $QNCX CEO, Dr Dirk Thye, prior to his current job, was CEO of Agenovir and had actually sold Agenovir to $VIR?

0 · Reply

dv1809 Oct. 10 at 2:35 PM

$QNCX just an R

0 · Reply

dv1809 Oct. 10 at 12:22 PM

$QNCX please guys, give me en TP

0 · Reply

Thestocktraderhubzee Oct. 10 at 10:19 AM

WATCHLIST OCT 10 2025 $QNCX Quince Therapeutics Announces Poster Presentation Of Patient-Reported Walking Capacity In Children With Ataxia-Telangiectasia At 54th CNS Annual Meeting $VIR Vir Biotechnology Doses First Patient In Phase 1 Trial Of Dual-Masked T-Cell Engager VIR-5500 For Prostate Cancer $BTC Bitcoin, Ethereum, Dogecoin, XRP Fall Amid Government Shutdown Uncertainty: Analytics Firm Says BTC Needs To Hold This Level In Short Term $TE T1 Energy Invests In Talon Photovoltaics; Texas Tunnel Oxide Passivated Contact Solar Fabs Total 9.8 GW Backed By One Basin Build Back America Act And Section 45X Credits $CDTX WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $199

1 · Reply

CoachHendo Oct. 10 at 9:08 AM

$QNCX

0 · Reply

Market Cap	95.61M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.45

Volume	125,200
Avg Vol	272,116
Day's Range	N/A - N/A
Shares Out	53.71M
Stochastic %K	3%
Beta	1.07
Analysts	Strong Sell
Price Target	$7.40